ASSESSMENT OF THE ECONOMIC VALUE OF DPP-4 INHIBITOR ALOGLIPTIN COMPARED WITH SITAGLIPTIN, SAXAGLIPTIN, AND LINAGLIPTIN
Author(s)
Pedrazzoli M1, Pasquini F1, Minda K2
1LSC Lifesciences Consultants, Milan, Italy, 2Takeda Pharmaceuticals, Glattpark-Opfikon (Zurich), Switzerland
OBJECTIVES Objective of this study is to provide additional evidence for decision making to payers assessing healthcare resource utilization, economic impact, and cost-effectiveness of DPP-4 inhibitor alogliptin compared with sitagliptin, saxagliptin and linagliptin, for the treatment of type-2 diabetes mellitus (T2DM). METHODS
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PDB34
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders